929 related articles for article (PubMed ID: 17909062)
1. Dynamics of the immune reaction to pancreatic cancer from inception to invasion.
Clark CE; Hingorani SR; Mick R; Combs C; Tuveson DA; Vonderheide RH
Cancer Res; 2007 Oct; 67(19):9518-27. PubMed ID: 17909062
[TBL] [Abstract][Full Text] [Related]
2. Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer.
Clark CE; Beatty GL; Vonderheide RH
Cancer Lett; 2009 Jun; 279(1):1-7. PubMed ID: 19013709
[TBL] [Abstract][Full Text] [Related]
3. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.
Garbe AI; Vermeer B; Gamrekelashvili J; von Wasielewski R; Greten FR; Westendorf AM; Buer J; Schmid RM; Manns MP; Korangy F; Greten TF
Cancer Res; 2006 Jan; 66(1):508-16. PubMed ID: 16397267
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.
Hiraoka N; Onozato K; Kosuge T; Hirohashi S
Clin Cancer Res; 2006 Sep; 12(18):5423-34. PubMed ID: 17000676
[TBL] [Abstract][Full Text] [Related]
5. Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts.
Roland CL; Dineen SP; Toombs JE; Carbon JG; Smith CW; Brekken RA; Barnett CC
Exp Biol Med (Maywood); 2010 Feb; 235(2):263-70. PubMed ID: 20404043
[TBL] [Abstract][Full Text] [Related]
6. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
[TBL] [Abstract][Full Text] [Related]
7. The immune network in pancreatic cancer development and progression.
Wörmann SM; Diakopoulos KN; Lesina M; Algül H
Oncogene; 2014 Jun; 33(23):2956-67. PubMed ID: 23851493
[TBL] [Abstract][Full Text] [Related]
8. Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice.
Grippo PJ; Nowlin PS; Demeure MJ; Longnecker DS; Sandgren EP
Cancer Res; 2003 May; 63(9):2016-9. PubMed ID: 12727811
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity in the HLA class I region in human pancreatic cancer.
Ryschich E; Cebotari O; Fabian OV; Autschbach F; Kleeff J; Friess H; Bierhaus A; Büchler MW; Schmidt J
Tissue Antigens; 2004 Dec; 64(6):696-702. PubMed ID: 15546343
[TBL] [Abstract][Full Text] [Related]
11. [Biological aspects of pancreatic cancer].
Tonel E; Carbone A; Scirelli T; Bellone G; Emanuelli G
Minerva Med; 2005 Apr; 96(2):87-94. PubMed ID: 16172578
[TBL] [Abstract][Full Text] [Related]
12. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
[TBL] [Abstract][Full Text] [Related]
13. Fas ligand expression in human pancreatic cancer.
Ohta T; Elnemr A; Kitagawa H; Kayahara M; Takamura H; Fujimura T; Nishimura G; Shimizu K; Yi SQ; Miwa K
Oncol Rep; 2004 Oct; 12(4):749-54. PubMed ID: 15375495
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.
Kojima K; Vickers SM; Adsay NV; Jhala NC; Kim HG; Schoeb TR; Grizzle WE; Klug CA
Cancer Res; 2007 Sep; 67(17):8121-30. PubMed ID: 17804724
[TBL] [Abstract][Full Text] [Related]
15. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF
Clin Cancer Res; 2007 Dec; 13(23):6947-58. PubMed ID: 18056169
[TBL] [Abstract][Full Text] [Related]
16. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.
Shen LS; Wang J; Shen DF; Yuan XL; Dong P; Li MX; Xue J; Zhang FM; Ge HL; Xu D
Clin Immunol; 2009 Apr; 131(1):109-18. PubMed ID: 19153062
[TBL] [Abstract][Full Text] [Related]
17. Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity.
Lin YC; Chang LY; Huang CT; Peng HM; Dutta A; Chen TC; Yeh CT; Lin CY
J Immunol; 2009 May; 182(10):6095-104. PubMed ID: 19414761
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells.
Leveque L; Deknuydt F; Bioley G; Old LJ; Matsuzaki J; Odunsi K; Ayyoub M; Valmori D
J Immunother; 2009; 32(2):101-8. PubMed ID: 19238008
[TBL] [Abstract][Full Text] [Related]
19. Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact.
Talmadge JE
Semin Cancer Biol; 2011 Apr; 21(2):131-8. PubMed ID: 21145968
[TBL] [Abstract][Full Text] [Related]
20. The significance of Treg cells in defective tumor immunity.
Kosmaczewska A; Ciszak L; Potoczek S; Frydecka I
Arch Immunol Ther Exp (Warsz); 2008; 56(3):181-91. PubMed ID: 18512029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
